These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
47 related articles for article (PubMed ID: 20189014)
1. Cardiovascular risk assessment and lipid modification: NICE guideline. Duerden M; O'Flynn N; Qureshi N Br J Gen Pract; 2015 Jul; 65(636):378-80. PubMed ID: 26120133 [No Abstract] [Full Text] [Related]
2. Have we reached the bottom of the bottomless pit- lessons from the recent lipid-lowering trials? Bansal M; Agarwala R Indian Heart J; 2018; 70(3):331-334. PubMed ID: 29961445 [No Abstract] [Full Text] [Related]
3. The American College of Cardiology 2018; a Starbuckian ODYSSEY and a Black Barbershop. Daniels MJ Cardiovasc Res; 2018 May; 114(6):e44-e46. PubMed ID: 29648584 [No Abstract] [Full Text] [Related]
6. The 11th Trial of a Cardiovascular Clinical Trialist: Coronavirus-2, Part 10: Summing Up. Frishman WH Cardiol Rev; 2023 Nov-Dec 01; 31(6):285-286. PubMed ID: 37678386 [No Abstract] [Full Text] [Related]
7. Defining a Clinically Meaningful Benefit in Cancer Clinical Trials: From the Perspectives of the Clinical Trialist, Patient, and Society. Moon DH; Chen RC JNCI Cancer Spectr; 2018 Oct; 2(4):pky039. PubMed ID: 31360869 [No Abstract] [Full Text] [Related]
8. Terje Pedersen: a pioneer trialist in preventive cardiology. Morris K Lancet; 2010 Feb; 375(9716):717. PubMed ID: 20189014 [No Abstract] [Full Text] [Related]
9. Terje Rolf Pedersen, MD: a conversation with the editor. Interview by William Clifford Roberts. Pedersen TR Am J Cardiol; 1999 Nov; 84(10):1234-45. PubMed ID: 10569335 [No Abstract] [Full Text] [Related]
10. Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. 2003. Shepherd J; Hunninghake DB; Barter P; McKenney JM; Hutchinson HG Atheroscler Suppl; 2004 Oct; 5(3):115-23. PubMed ID: 15531284 [No Abstract] [Full Text] [Related]
11. Cardiovascular primary prevention: how high should we set the bar? Prasad V; Vandross A Arch Intern Med; 2012 Apr; 172(8):656-9; discussion 659. PubMed ID: 22529231 [TBL] [Abstract][Full Text] [Related]
12. Implications of the heart protection study for reducing coronary events in high-risk patients. Brown WV; Davis W; Harris M Curr Atheroscler Rep; 2003 Sep; 5(5):358-63. PubMed ID: 12911845 [No Abstract] [Full Text] [Related]
13. [The factors that condition the efficacy of and indications for statins in cardiovascular prevention]. Pintó Sala X Aten Primaria; 1999 Mar; 23(4):227-30, 232-4. PubMed ID: 10333608 [No Abstract] [Full Text] [Related]